More than 20 years ago, GLP-1 receptor agonists entered the market as type 2 diabetes therapies, building steady commercial success on the strength of durable A1C reduction, once-weekly dosing, and a low risk of hypoglycemia. The first such therapy was exenatide, introduced in 2005, followed by liraglutide (2010), dulaglutide (2014), and semaglutide (2017).
But for all that momentum, the class had not yet reached blockbuster status. That trajectory changed in 2021 with the approval of Wegovy for chronic weight management, marking a clear inflection point for the class. The off-label use of Ozempic for weight loss that gained momentum around 2022-2023 ushered in the true blockbuster era, rapidly transforming GLP-1s into one of the fastest-growing drug classes in pharmaceutical history.
The class’s success ever since has been driven by four compelling factors: strong and durable glycemic control in type 2 diabetes; meaningful weight loss; a low risk of hypoglycemia; and favorable cardiovascular outcomes. Rapid multi-indication expansion into areas like obstructive sleep apnea reinforced that momentum, and the growth trajectory shows no sign of slowing.
Coverage Dynamics: One Molecule, Different Rules
Medicare was long barred from covering GLP-1s for weight loss alone, meaning that the same molecule which was reimbursed for diabetes was denied for obesity. That changed on July 1, 2026, when CMS launched the Medicare GLP-1 Bridge, a time-limited demonstration allowing eligible Part D enrollees to access GLP-1s for weight management at $50/month through December 2027.
Participating manufacturers agreed to supply the drugs at a net price of $245 per month. Because the demonstration sits outside the Part D benefit, that copay does not count toward a beneficiary’s Part D out-of-pocket cap. Ozempic and Wegovy are the same molecule at different doses, yet Medicare treats them very differently by indication (see chart below).
| Indication (Brand) | Medicare Coverage Pathway | Beneficiary Cost |
| Type 2 diabetes (Ozempic) | Covered under standard Part D benefit | Standard Part D cost sharing; typically subject to prior authorization |
| Weight management only (Wegovy injection or pill) | Excluded from Part D by statute; available through the Medicare GLP-1 Bridge demonstration | $50/month; copay does not count toward the Part D out-of-pocket cap |
| Cardiovascular risk reduction in overweight/obese patients with established CV disease (Wegovy) | Covered under standard Part D benefit as an FDA-approved, Part D-eligible indication | Standard Part D cost sharing |
Sources: CMS, Medicare GLP‑1 Bridge program materials and press releases; Novo Nordisk Wegovy coverage information.
The Indication Gap Deepens on the Commercial Side
Commercial coverage follows this same indication-specific split and adds another layer on top. Employers routinely carve weight-management drugs into a separate benefit category. Ozempic sits in a preferred formulary tier for 81% of commercial lives, versus 63% for Wegovy (see chart, below).
Both are broadly covered, but Wegovy is more often seen on the more restricted coverage tier (22% vs. 8%), and is excluded outright roughly six times more often. Lower-quality access translates into higher out-of-pocket costs for Wegovy patients on the same molecule.
| Drug (Indication) | Covered | Covered (PA/ST) | Preferred | Preferred (PA/ST) | Not Covered |
| Ozempic (Diabetes) | 0% | 8% | 20% | 61% | 1% |
| Wegovy (Obesity) | 1% | 22% | 6% | 57% | 6% |
Source: Norstella Analytics, Aug 2026; same-molecule comparison of semaglutide across ~173M commercial lives. Includes commercial formulary-plan combinations from Express Scripts, CVS Caremark, OptumRx, UnitedHealthcare, Cigna, Anthem, BCBS plans, and Highmark.
As GLP-1s gain additional approvals in cardiovascular disease, sleep apnea, and MASH, each new indication comes with its own coverage rules. For manufacturers, indication-level evidence is now as consequential as the label itself. For payers, the question becomes whether the cost of lifelong treatment is outweighed by the long-term savings generated by fewer cardiovascular events, slower progression to renal failure, and the averted treatment of obesity-related comorbidities in these populations.
Oral Formulations, Multi-Receptor Therapies, and the Patent Cliff
Recent innovations in the metabolic space include dual- and triple-hormone receptor agonists designed to enhance glycemic control and amplify weight reduction. Tirzepatide’s approval as the first dual GIP-GLP-1 receptor agonist marked a significant milestone, while the next generation of therapies in development includes glucagon-GLP-1 dual agonists; amylin-GLP-1 combinations; GIP-GLP-1-glucagon triple agonists; and GLP-1 receptor agonist-GIP receptor antagonist antibodies. The field has shifted away from single-pathway GLP-1 activation toward broader, multi-receptor metabolic modulation.
Another major evolution is the move toward oral formulations. The FDA’s December 2025 approval of the Wegovy pill — the first oral GLP-1 for weight loss — has the potential to significantly expand the market. An oral formulation removes the key barriers associated with injectables: clinic-dependent initiation, cold-chain storage, and patient resistance to injections. Non-peptide, small-molecule oral drugs may offer additional advantages in manufacturing scale and supply reliability. How adoption will split between oral peptide therapies and oral small-molecule GLP-1s remains to be seen.
The class is also entering a patent-cliff phase. Liraglutide’s branded products — Victoza for type 2 diabetes, and Saxenda for weight loss — saw their first generic competition arrive in 2024 and 2025, respectively. In 2026, semaglutide’s compound patent expired in several major markets, including India, China, Brazil, and South Africa. Subsequently, India has seen an immediate wave of generic launches, while China is advancing multiple semaglutide programs through late-stage clinical trials. While generics will improve access and affordability, GLP-1s retain strong lifecycle-extension opportunities through new indications and labeling.
Navigating Payer Scrutiny, Generic Pressure, and Global Competition
GLP-1 development remains highly attractive to manufacturers, as these drugs are able to address obesity, diabetes, cardiovascular disease and liver disease within a single therapeutic class. The current oral innovation and expanding generic access only add to their potential.
At the same time, the path forward is increasingly complex, shaped by global pricing pressure, manufacturing and formulation challenges, the need to justify premium pricing, and heightened scrutiny around long-term safety. How this class navigates generic competition, payer expectations, and regulatory oversight will ultimately define the next phase of its evolution.
To stay ahead, manufacturers of GLP-1s should invest now in indication-level evidence, particularly for cardiovascular, renal, and hepatic outcomes, that lets payers tie coverage to demonstrated long-term savings rather than list price alone. Embracing oral and lower-cost formulations, and competing on access and affordability as generics arrive, will secure durable share while also benefiting the patients and payers footing the bill. Doing so will help ensure the class’s continued success and ease its path into this next chapter, beyond blockbuster status and toward a lasting role in chronic disease management.
To explore MMIT’s gold-standard formulary, coverage, and policy intelligence using our purpose-built AI querying tool, learn more about our advanced analytics experience, Mosaic.
